Patent Application for Gilead’s Lenacapavir Opposed: Saving Generics of HIV Drugs?
SpicyIP
OCTOBER 1, 2024
The Indian Patent Office (IPO) is set to hear objections against Gilead Sciences’ patent claims for Lenacapavir, an HIV drug. This situation highlights the ongoing struggle between patent protections and access to essential medicines. The looming threat is the pending patent applications by Gilead in India.
Let's personalize your content